WARF: P05159US



Hector DeLuca, Lori Plum, Margaret Clagett-Dame

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a new vitamin D analog.
OVERVIEWVitamin D is a highly potent regulator of calcium homeostasis and plays an established role in cellular differentiation. A recently discovered class of vitamin D analogs, the 19-nor-vitamin D compounds, shows a selective activity profile with high potency in inducing cellular differentiation and very low calcium mobilizing activity. These features make the 19-nor compounds potentially useful as therapeutic agents for a number of disorders.
THE INVENTIONUW-Madison researchers have developed a new vitamin D analog, 2-methylene-19,21-dinor-1α-hydroxy-bishomopregnacalciferol. Compared to 1α,25-dihydroxyvitamin D3, this compound exhibits relatively high binding to vitamin D receptors, very low intestinal calcium transport activity, and very low ability to mobilize calcium from bone. It also displays relatively high cell differentiation activity, making it potentially useful as an anti-cancer agent or a therapeutic agent for treating skin conditions.
  • Potential anti-cancer agent, especially against leukemia, colon, breast and prostate cancers
  • Preventing or treating obesity and reduce body fat
  • Treating skin diseases, such as psoriasis, as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion
  • Potential for treating immune disorders in humans, including multiple sclerosis, lupus, diabetes mellitus, host-versus-graft reaction and organ transplant rejection
  • Prospective treatment for inflammatory diseases such as rheumatoid arthritis, asthma and inflammatory bowel diseases
  • Promising treatment for renal osteodystrophy and osteoporosis
  • Treating other disorders, including acne, alopecia and hypertension
For More Information About the Inventors
Contact Information
For current licensing status, please contact Rafael Diaz at or 608-960-9847.
The WARF Advantage

Since its founding in 1925 as the patenting and licensing organization for the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.